This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Acute Traumatic Pain
and you are
between 18 and 70
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Administration of midazolam with morphine in patients with severe acute pain is a routine practice in the management of pre- and post-operative patients but has not been evaluated in pre-hospital setting. The investigators aim to evaluate the co-analgesic effect of midazolam in the pre-hospital management of traumatic patients with severe acute pain. In a multicenter prospective randomized double-blind placebo-controlled trial, the investigators would like to compare the analgesic effect and safety of the intravenous morphine 0.10 mg/kg and midazolam 0.04 mg/kg with the intravenous morphine 0.10 mg/kg and placebo in pre-hospital traumatic adults. Assessment will be done at the baseline using a validated numeric rating scale (NRS). The primary outcome will be the proportion of patients with a pain score less than or equal to 3 after 20 minutes. The secondary outcomes will be in between-group comparison of: the treatment safety, pain score every 5 minutes during 30 minutes and the total morphine dose required until obtaining a pain score less than or equal to 3.

Provided treatments

  • Drug: Midazolam
Tris trial is registered with FDA with number: NCT01731184. The sponsor of the trial is Centre Hospitalier de Cornouaille and it is looking for 100 volunteers for the current phase.
Official trial title:
Randomized Double-blind Placebo-controlled Trial: Administration of Morphine-Placebo vs. Morphine-Midazolam in Pre-hospital Traumatic Patients With Severe Acute Pain.